生物制药明星公司康方生物3月30日晚间在港交所发布2024年度财报,2024年,集团总收入为21.24亿元人民币,同比下降53.08%;截至2024年12月31日止年度亏损为5.01亿元,而截至2023年12月31日止年度盈利为19.42亿元。2024年,康方生物新药销售收入超20亿元,同比增长25%,创下新高,这令投资者们感到鼓舞。公司核心产品双抗卡度尼利、依沃西均成功被纳入国家医保目录,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.